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Background: Blue- green algae is one of the most nutrient dense foods which is rich in substances that have useful
effects on human health. The purpose of this study was to evaluate the effectiveness of a water- soluble extract of the
cyanophyta Aphanizomenon Flos-aquae (StemtechTM) as a functional supplement on CD markers, lipid profile, glucose
levels as well as its side effects in Iranian patients with type 2 diabetes.
Methods: During this randomized, double-blind, placebo-controlled trial 49 type 2 diabetic patients, aged between 20
and 60 years with a HbA1C≥ 7.5 %, were allocated. Patients were divided into two groups of placebo and treated with
an equal ratio 1:1. The subjects in StemtechTM group received one capsule of StemFlo (508 mg) before breakfast and
two capsules of StemEnhance (500 mg) after each meal for a period of 12 weeks, and placebo group was instructed to
take placebo with the same pattern. During the intervention period, subjects were asked to keep usual diet and
prohibited to take any functional foods or dietary supplements. Metabolic panel has been measured as the primary
outcome of study at the beginning and end of the intervention period via blood sampling.
Results: StemtechTM supplementation for 12 weeks decreased fasting blood glucose (FBG) and Glycatedhemoglobin
(HbA1c). Mean serum chemistry parameters (Triglyceride, Total Cholesterol, LDL, HDL, CRP, AST, ALT, BUN and Creatinine)
as well as CD 34+, IL-6, TNF-α in treated and control groups before and after the study showed no considerable
dissimilarities.
Conclusion: StemtechTM intervention brought in positive consequence on blood glucose levels in Iranian patients
with type 2 diabetes, consequently suggests the StemtechTM as a functional food for the management of diabetes.
Keywords: Type 2 Diabetes, CD34, Aphanizomenonflos-aquae(AFA), StemtechTMIntroduction
Diabetes mellitus, as a multi-factorial disease, is charac-
terized by chronic hyperglycemia due to insulin resist-
ance and defect in insulin secretion and/or insulin
action caused by Langerhans islets β-cell failure. Other
primary defects responsible for the development of dia-
betes are increasing in hepatic glucose production and
decrease in peripheral glucose utilization [1]. It is one of* Correspondence: m_ebrahimi49@yahoo.com
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creativecommons.org/publicdomain/zero/1.0/the most important worldwide health problems that is
estimated to affect at least 5 % of the global population
by the year 2025 [2, 3]. Currently, the available therapy
for diabetes includes insulin injection and various oral
anti-diabetic agents such as sulfonylureas, Thiazolidine-
diones, α-Glucosidase inhibitors, etc. These drugs are
used as monotherapy or in combination to achieve bet-
ter glycaemic control. Diabetes mellitus has been classi-
fied into two forms; type 1 and type 2. Type 1 diabetes is
caused by autoimmune destruction of β- cells, therefore,
treatment of type 1 diabetes depends on exogenous insu-
lin. Type 2 diabetes is more prevalent than type 1 and is
considered a heterogeneous disease.ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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foods which is rich in substances that have useful effects
on human health. This substance has a high concentra-
tion of vitamins, minerals and enzymes with a complete
spectrum of essential and non-essential amino acids that
are all easily absorbed by the body. Due to these proper-
ties, a large number of researchers were interested in
employment of blue-green algae as food supplementa-
tion. Several blue-green algae, including Aphanizome-
nonflos-aquae (AFA) showed protective effects in the
classical AMES test [4], antibacterial and antioxidant
properties, glucose and cholesterol-regulatory effects as
well as host immune system modulation [4–6]. Numer-
ous studies have been performed to estimate the results
of blue-green algae supplementation on promoting
health and controlling a variety of disorders in humans
[7]. There are increasing scientific and clinical evidences
for its role in controlling chronic diseases such as arth-
ritis [8] and cancer [9, 10]. This substance can enhance
the phagocyte activity in macrophages [11, 12]. More-
over, inhibition of allergic reactions in rodents has been
reported by this agent [13, 14]. However, there is not
any authentic report about AFA extracts and diabetes
some studies reported the lipid-lowering effect of blue-
green algae in healthy [15] and diabetic patients [16].
It has been shown that blue-green algae increases the
stem cells trafficking or homing in animals through induc-
tion of a transient boosting in the population of stem cells
in animal’s circulatory systems [17, 18]. Two of these nat-
ural products are Stem Flo and StemEnhance (STEM Tech
Health Sciences, San Clemente, CA, USA) (StemtechTM),
which are extracted from AFAplant [19, 20].
Given the importance of diabetes mellitus, the purpose
of this study is to evaluate the safety and efficacy of
StemtechTM (StemEnhance and StemFlo) on lipid pro-
file, glycemic control, CD markers in patients with type
2 diabetes.
Materials and methods
This study was a double-blind, parallel randomized clinical
trial (RCT) on Type 2 diabetic patients who were aged be-
tween 20 and 60 years with a Glycated hemoglobin
(HbA1c) ≥ 7.5 %. Patients were allocated into two groups
of treatment (StemTech group) and placebo, based on
permuted balanced block randomization. Forty nine Stem-
Tech patients (9 male, 40 female) were enrolled in this
study. During the follow-up period four patients (16 %) in
the placebo group and three patients (12 %) inStemTech
group were withdrawn which was mostly because of nau-
sea. Subsequently the number of patients in the control
group dropped to 20 in the placebo and to 22 from Stem-
Tech group. The study was approved by ethic committee
and registered in the Iranian Registry of Clinical Trials
(IRCT) withcode201108074920N2. All patients signedthe informed consent form. Key inclusion criteria were set
as:both sexes, aged between 18–70 years, type 2 diabetic
patients with HbA1c ≥ 7.5 % and <10 %. Patients who had
a systemic or chronic illness, diabetic complications such
as diabetic nephropathy, malignancy, history of active
inflammatory illness, were pregnant, intended to become
pregnant during the study period or were breast fed
excluded from the study. Moreover, patients who were
on corticosteroid therapy, radiotherapy, chemotherapy
or any immuno- suppressive drug, consumed alcohol,
used vitamin or mineral supplements in the last
2 months, or their diabetic treatments were changed
during the last two months were excluded from the
study. The diagnosis of diabetes was based on American
Diabetes Association Criteria [21].
Blood was drawn after a minimum of 12 h fasting at
first (beginning of the intervention) and last visit (end of
study) and biochemical, inflammatory and antioxidant
markers were measured in collecting samples. An-
thropometric parameters, nutrient intakes and quality of
life were assessed at baseline.
The participants were interviewed and life-style, food
expenditure, body weight, height and body mass index
(BMI) were measured. The systolic and diastolic blood
pressures were measured before and after study using an
automatic blood pressure calculator after a 10 min rest.
The subjects in StemTech group received one capsule
of StemFlo before at breakfast and two capsules of Ste-
mEnhance after each main meal for a period of 12 weeks.
It means that they received 90 StemFlo (508 mg of
Enzyme Blend Nattozime,Serrazime,Papain,Bromelain,
Protease 6.0, Protease 4.5, Indian Gooseberry fruit,
Citrus Bioflavonoid,black-currant extract, Mangos teen
fruit and rind, Cats claw bark and Turmeric root ex-
tract) and 180 StemEnhance (500 mg Aphanizome-
nonflos-aquae extract per capsule) (Stemtech Canada
Inc). The placebo group took placebo with the same
pattern of StemFlo and StemEnhance.
The observance for all participants was completed
by telephoned one every two weeks. Biochemical pa-
rameters were measured using the following materials:
Malondialchehyche(MDA) (ELISA Kit, Cat. No:E1371Hu),
Interleukin 6(IL-6) (ELISA Kit, Cat. No:E0090Hu) and
TNF-alpha (ELISA Kit, Cat. No: E0082Hu). CD 34 was
measured as primary outcome of study at the beginning
and end of intervention period in the blood sample. The
averages actual numbers of CD34 + cells were calculated
by multiplying the percent CD34+ cells, based on flow-
cytometry on triplicate samples from each time point.
Any adverse event, including neurotoxin activity, hep-
atotoxicity, allergic and skin reactions were recorded. If
the adverse effect were serious enough to require med-
ical attention, it had to be reported within a few days.
Then Data and Safety Monitoring Board (DSMB) were
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not blinding should be removed and the patient should
or should not be excluded from the study.
In case of fatal or severe event requiring hospital ad-
mission, reporting should be prompted at the same day
to the responsible officer in Stemtech Company by fax.
Statistical analysis
Data were presented as mean ± SD (Standard deviation).
The chi - square test was performed to determine differ-
ences at baseline in frequencies of categorized variables
between the groups and mean differences were analyzed
by analysis of covariance (ANCOVA). The paired t-test
was used to analyze mean differences for all measured
parameters between baseline and the end of the interven-
tion period. To demonstrate the association between base-
line blood profiles and mean change of various parameters,
partial correlation coefficients analysis was conducted. Data
within each group were analyzed by repeated measures
analysis of variance to establish significant differences in
treatment. Statistical analyses were performed with SPSS
version 16.0 statistical package for Windows (SPSS Inc.,
Chicago, Illinois). The P value of less than 0.05 was consid-
ered statistically significant.
Results
Subjects were randomly allocated to receive placebo or
StemTechTM for 16 weeks (Fig. 1). The duration of diabetes
varied from 2 to 22 years (mean and SD:8.8 ± 5.6). The age
range was from 33 to 74 years (55.4 ± 7.9 years). There was
no significant difference in baseline characteristics,Fig. 1 Flowchart of sample enrollment in this studyincluding age, sex, weight, BMI, waist circumference,
hip circumference, duration of diabetes, systolic and
diastolic blood pressure, cigarette smoking and alco-
hol consumption between two groups (Table 1). The
biochemical parameters of the two groups also
showed no significant difference in the baseline.
As it is shown in Table 2, no significant differences in
plasma levels of MDA, TNF-a, IL-6, and CD34 percent-
age was observed before and after intervention in pla-
cebo and StemTechTM groups.
There was a non-significant decrease in the fasting
blood glucose and a significant decrease in HbA1c in
StemTechTM group at the end of the study compared to
the baseline (Table 3). Safety of StemTechTM was con-
firmed by other biochemical determinates.
Evaluation of hematologic factors in the placebo group
showed a difference in white blood cells (WBCs). No
further changes in other factors in both groups were
noticed.
During the study there was only one person in the pla-
cebo group who complained about nausea and no other
significant side effects were reported.
Discussion
Diabetes not only reduces the value and extent of life, but
also has enormous health-caring related costs. Global
health expenditures for diabetes in 2030 will be 30–34 %
more than 2010 [22]. The most recent WHO assessment
shows that 171 million people worldwide are diabetic and
this trend is going to be more than twice in the year 2030
[23]. There is a mounting concern to find a safe and
Table 1 Baseline characteristics of subjects between two studied groups
Placebo (n = 24) StemTechTM (n = 25) P-value
Age (years) 55.7 ± 9.3 55.2 ± 6.4 0.853
Sex (Male/Female) 6/18 3/22 0.289
Weight (Kg) 77.0 ± 13.7 72.1 ± 10.8 0.178
BMI (kg/m2) 29.1 ± 4.8 29.0 ± 3.3 0.960
Waist circumference (cm) 104.2 ± 10.9 100.4 ± 9.8 0.347
Hip circumference (cm) 58.7 ± 12.7 55.3 ± 15.3 0.541
Duration diabetes (years) 9.0 ± 6.2 8.5 ± 5.0 0.747
Systolic blood pressure (mmHg) 12.6 ± 1.6 12.3 ± 1.6 0.653
Diastolic blood pressure (mmHg) 7.8 ± 0.7 7.4 ± 1.1 0.169
Heart rate (n) 71.7 ± 10.1 69.4 ± 10.3 0.507
Current smoking (%) 3.0 (13.0) 0.0 (0.0) 0.233
Alcohol consumption (%) 1.0 (4.3) 2.0 (8.7) 1.000
Data are mean ± Standard Deviation and number (%) where indicated
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supplement in order to cause the problem. Spirulina, a
filamentous cyanobacteriumis an appropriate candidate,
which United Nations World Food Conference confirmed
Spirulina as “the best for tomorrow” [24].
Some beneficial effects of Blue-Green Alga extract on
health of diabetic animal have been reported [25, 26].
Our main effort in this randomized clinical trial was to
consider the role of StemtechTM on HbA1C, lipid profile,
glycemic control, CD markers, as well as its side effects
in patients with type 2 diabetes. We showed in patients
with type-2 diabetes mellitus, StemtechTM diet could
lower the HbA1c. Our results are on the same page with
other studies which have measured the effect of blue-
green algae on glucose levels in diabetic rats. The in-
creased HbA1c is produced when the level of
hemoglobin decreased and it leads to the highest level of
blood glucose. Animals who were given Blue-Green
Algae extract, which is a rich source of iron, had higher
levels of hemoglobin, which is considered as the main
cause of HbA1C level reduction [27]. They established
that water-soluble fraction was useful in lowering the
fasting serum glucose level [28]. And also they showed
that rats, who lost their weight, after Spirulina treatmentTable 2 Comparison of cell marker, immunological parameters and
studied groups
Placebo P
Before After
TNF-α (pg/ml)a 118.4 (104.8-226.8) 107.3 (100.1-304.4) 0
IL-6 (pg/ml)a 43.5 (38.7-72.5) 43.8 (38.3-99.7) 0
MDA (μmol/l)a 6.0 (5.0-10.5) 6.3 (5.1-12.5) 0
CD −34+ (%) 0.72 ± 0.15 0.88 ± 0.20 0
TNF- α; Tumor necrosis factor alpha,IL-6; Interleukin-6, MDA; malondialdehyde
aData was shown as Median (Inter Quartile Range) and analyzed by Non-Parametricregained their body weight. A significant decrease in the
fasting blood sugar level of patients after 21 days of 2 g/
day total Spirulina supplementation has been shown
[16]. In another study, the oral administration of 15 mg/
kg Spirulinafor 45 days in diabetic rats significantly re-
duced the blood glucose level [25]. There was an
emphasize on crude extract and insulin-like protein of
Spirulina instead of an aqueous and ethanolic extracts
[29]. Liver levels of triglycerides and phospholipids posi-
tively and significantly responded in rats which was fed
with a diet supplemented with 5 % Spirulina and either
60 % glucose or 60 % fructose [30].
Decreasing the blood glucose concentration in diabetic
rats probably is done through stimulation of the β-cells
of Langerhans islets to increase the production of insu-
lin. The possible mechanism by which Spirulina pro-
duces its antihyperglycemic effects may be through
potentiating of the pancreatic secretion of insulin from
islet β-cell or due to enhancement of transport of blood
glucose to the peripheral tissue [29]. This could possibly
be due to the high fiber content of Blue-Green Alga that
interferes with the glucose absorption [31] or probable
action of producing polypeptides after digestion of Blue-
Green Algae [16]. Several studies support that theantioxidant level before and after intervention among two
-value StemTechTM P-value
Before After
.481 114.1 (99.2-248.4) 109.0 (101.4-353.8) 0.230
.313 42.1 (39.6-66.6) 43.4 (36.8-81.5) 0.584
.296 6.0 (4.9-11.3) 6.5 (5.4-26.0) 0.289
.101 0.77 ± 0.15 0.82 ± 0.21 0.488
Test and other were shown as mean ± Standard Deviation
Table 3 Comparison of biochemical assessments before and after of study among two studied groups
Placebo P-value StemTechTM P-value
Before After Before After
FBG (mg/dl) 179.9 ± 63.3 157.4 ± 39.9 0.217 187.9 ± 54.9 167.2 ± 66.2 0.079
HbA1c (%) 8.5 ± 1.8 8.2 ± 1.6 0.393 9.1 ± 1.8 8.3 ± 1.6 0.006
Triglyceride (mg/dl) 214.1 ± 106.9 155.7 ± 59.8 0.300 173.9 ± 74.8 176.5 ± 74.3 0.810
Total cholesterol (mg/dl) 174.9 ± 62.7 170.1 ± 42.9 0.657 174.9 ± 25.5 172.1 ± 27.0 0.646
LDL-C (mg/dl) 81.8 ± 40.7 94.9 ± 35.9 0.127 90.0 ± 20.9 89.5 ± 21.0 0.913
HDL-C (mg/dl) 40.5 ± 8.8 41.0 ± 9.6 0.780 43.6 ± 7.8 43.9 ± 9.2 0.840
CRP (mg/L) 2.7 ± 2.4 2.5 ± 3.0 0.621 2.9 ± 2.7 3.0 ± 2.5 0.347
AST (U/L) 22.1 ± 8.6 21.9 ± 8.3 0.927 23.4 ± 15.3 21.5 ± 9.7 0.334
ALT (U/L) 33.3 ± 26.1 29.3 ± 18.8 0.171 29.3 ± 13.7 26.7 ± 10.4 0.200
BUN (mg/dl) 25.9 ± 15.6 25.8 ± 15.2 0.950 22.8 ± 10.4 22.3 ± 8.3 0.807
Creatinine (mg/dl) 0.99 ± 0.19 0.95 ± 0.18 0.053 0.95 ± 0.16 0.93 ± 0.13 0.433
FBG; Fasting blood glucose, HbA1c; Glycated hemoglobin, LDL-C; Low-density lipoprotein Cholesterol, HDL-C; high- density lipoprotein Cholesterol, CRP; C- reactive
protein, AST; aspartate aminotransferase, ALT; Alanine transaminase, BUN;blood urea nitrogen, WBC; white blood cell, RBC; red blood cell
Data are mean ± Standard Deviation and percent where indicated
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row stem cells in the target tissue constitute a natural
phenomenon of healing in the human body [32–35].
Mean serum chemical parameters (Triglyceride, Total
Cholesterol, LDL, HDL, CRP, AST, ALT, BUN and Cre-
atinine) in treated and control groups before and after
the study showed no significant differences which indi-
cates the safety of StemtechTM. These findings strength-
ened the results of other studies showing that even
higher exposure to StemEnhance does not lead to tox-
icity [19, 36–38]. Levent Dirikolu in 2010 demonstrated
that feeding StemEnhance at 600 mg/kg for two weeks
was not toxic to Wistar rats. It also did not affect the be-
havior or physical assessments of the rats. The dose of Ste-
mEnhance tested in the rat was approximately equal to20
times higher than the maximum label-recommended daily
dose for human use. Consequently, it would appear that
no toxicological risk is associated to the use of StemEn-
hance at label doses [39]. Not only higher doses of Spiru-
lina (up to 73 %) did not show any considerable difference
in experimental and control animals, but it also produced
an increase in the relative weight of some viscera [40].
Apparently AFA is well tolerated and good supply of poly-
unsaturated fatty acids [41, 42] which may increase the
nutritional value of the diet.
Some studies have shown that the consumption of one
gram of StemtechTM led to a considerable increase in
the percentage of circulating CD34+ cells after one hour
[19]. Also, they proved that mobilization of bone mar-
row CD34+ cells was related to L- selectin ligand con-
tained in Stem Enhance which caused down regulation
of CXCR4 chemokine receptor. The interruption of the
binding of SDF-1 to CXCR4 chemokine receptor which
leads to mobilization of CD34+ stem cells in rats isdetectable between 2–4 weeks [43]. As we shown in
Table 2 there was no significant differences in cell markers
and antioxidant before and after intervention in both
groups A and B and it goes without saying that our inter-
vention period of 12 weeks was enough to see a difference.
Triglyceride, total cholesterol, LDL and HDL did not
change significantly in our two groups before and after
intervention, however, some studies showed that Blue-
Green Algae inhibits intestinal cholesterol absorption
and decreases the hepatic lipids and leads to attenuation
of plasma total cholesterol, and triglyceride concentra-
tions. The anti-inflammatory function of the BGA is me-
diated, at least in part, by inhibiting the Nuclear Factor
Kappa B pathway to decrease the production of pro-
inflammatory mediators. BGA can also decrease oxida-
tive stress due to their free radical scavenging activity
and inhibition of lipid per-oxidation [44]. According to
the fact that cell marker, immunological parameters
showed no significant changes statistically (Table 2), the
power of each parameter is calculated, which was 60-
70 % in Placebo and 15-20 % in StemtechTM groups, re-
spectively. Therefore, it seems that the evidences for the
effectiveness of StemtechTM on these parameters cannot
be declined easily. In order to find more authentic re-
sults, we need some studies with larger sample size.
Conclusion
Even though, hypoglycemic property of Blue-Green Algae
extracts has been reported earlier, this study is the first ran-
domized clinical trial of StemtechTM in a group of Iranian
diabetic patients. StemtechTM intervention brought in favor-
able effects on HbA1c in our diabetic patients consequently
suggest StemtechTM as a functional food in management of
diabetes.
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